Mycobacterial antibody levels and immune restoration disease in HIV patients treated in South East Asia

Biomarkers in Medicine

Volumn 5, Issue 6, 2011, Pages 847-853

  Sumatoh, Hermi R ^a   Oliver, Benjamin G ^a   Kumar, Manoj ^b   Elliott, Julian H ^c,d,e   Vonthanak, Saphonn ^f,g   Vun, Mean Chhi ^g   Singh, Sarman ^b   Agarwal, Upasna ^h   Kumar, Amitabh ^h   Tan, Hong Yien ⁱ   Kamarulzaman, Adeeba ⁱ   Yunihastuti, Evy ^j   Saraswati, Heni ^j   Price, Patricia ^a,k  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^b ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

^c ALFRED HOSPITAL   (Australia)

^d BURNET INSTITUTE   (Australia)

^e UNIVERSITY OF NEW SOUTH WALES   (Australia)

^f Dermatology and STD   (Cambodia)

^g National Institute of Public Health   (Cambodia)

^h LRS Institute of Tuberculosis and Respiratory Diseases   (India)

ⁱ UNIVERSITY MALAYA MEDICAL CENTRE   (Malaysia)

^j UNIVERSITY OF INDONESIA   (Indonesia)

^k ROYAL PERTH HOSPITAL   (Australia)

more..

Author keywords

antibody; antiretroviral therapy; HIV; immune restoration disease; Mycobacterium tuberculosis

Indexed keywords

ANTIRETROVIRUS AGENT; BACTERIUM ANTIBODY; IMMUNOGLOBULIN G ANTIBODY; LIPOARABINOMANNAN; MYCOBACTERIUM ANTIBODY; MYCOBACTERIUM ANTIGEN; TUBERCULIN; TUBERCULOSTATIC AGENT; UNCLASSIFIED DRUG;

ADULT; ANTIBODY BLOOD LEVEL; ANTIBODY TITER; ARTICLE; ASIAN; BLOOD SAMPLING; CAMBODIA; CD4 LYMPHOCYTE COUNT; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE EXACERBATION; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMORAL IMMUNITY; IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME; INDIA; INDONESIA; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALAYSIA; MOLECULAR WEIGHT; MYCOBACTERIUM TUBERCULOSIS; PROSPECTIVE STUDY; TREATMENT DURATION; TUBERCULOSIS;

ADULT; AGED; ANTI-HIV AGENTS; ANTIBODIES, BACTERIAL; ASIA; COHORT STUDIES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HIV INFECTIONS; HUMANS; IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME; IMMUNOGLOBULIN G; LIPOPOLYSACCHARIDES; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; MYCOBACTERIUM TUBERCULOSIS; PROSPECTIVE STUDIES; TUBERCULOSIS;

EID: 82755166894     PISSN: 17520363     EISSN: 17520371     Source Type: Journal    
DOI: 10.2217/bmm.11.79     Document Type: Article

References (25)

1. Lazarous DG, O'Donnell AE. Pulmonary infections in the HIV-infected patient in the era of highly active antiretroviral therapy. An update. Curr. Infect. Dis. Rep. 9(3), 228-232 (2007). (Pubitemid 46744739)
2. Blanc FX, Havlir DV, Onyebujoh PC, Thim S, Goldfeld AE, Delfraissy JF. Treatment strategies for HIV-infected patients with tuberculosis. Ongoing and planned clinical trials. J. Infect. Dis. 196, 46-51 (2007).
3. Price P, Murdoch DM, Agarwal U, Lewin SR, Elliot JH, French MA. Immune restoration diseases reflect diverse immunopathological mechanisms. Clin. Microbiol. Rev. 22, 651-663 (2009).
4. Meintjes GA, Lawn SD, Scano F et al. Tuberculosis immune reconstitution inflammatory syndrome. Case definitions for use in resource-limited settings. Lancet Infect. Dis. 8(8), 516-528 (2008).
5. Bourgarit A, Carcelain G, Martinez V et al. Explosion of tuberculin-specific Th1-responses induces immune restoration syndrome in tuberculosis and HIV coinfected patients. AIDS 20(2), F1-F7 (2006).
6. French MA. Immune reconstitution inflammatory syndrome. A reappraisal. Clin. Infect. Dis. 48, 101-107 (2009).
7. Tan DBA, Yong YK, Kamarulzaman A et al. Immunological profiles of immune restoration disease presenting as mycobacterial lymphadenitis and cryptococcal meningitis. HIV Med. 9(5), 307-316 (2008). (Pubitemid 351517278)
8. Skolimowska K, Meintjes G, Wilkinson KA et al. Effect of steroids on T-cell expansions in HIV-tuberculosis immune reconstitution inflammatory syndrome. Presented at: 5th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention. Cape Town, South Africa 19-22 July 2009 (Abstract TUPEB146).
9. Stone SF, Lee S, Keane NM, Price P, French MA. Association of increased hepatitis C virus (HCV)-specific IgG and soluble CD26 dipeptidyl peptidase IV enzyme activity with hepatotoxicity after highly active antiretroviral therapy in human immunodeficiency virus-HCV-coinfected patients. J. Infect. Dis. 186(10), 1498-1502 (2002). (Pubitemid 35286121)
10. Stone SF, Price P, Tay-Kearney ML, French MA. Cytomegalovirus (CMV) retinitis immune restoration disease occurs during highly active antiretroviral therapy-induced restoration of CMV-specific immune responses within a predominant Th2 cytokine environment. J. Infect. Dis. 185(12), 1813-1817 (2002). (Pubitemid 34615479)
11. Yunihastuti E, Lee S, Gani RA, et al. Antibody and markers of T-cell activation illuminate the pathogenesis of HCV immune restoration disease in HIV/HCV co-infected patients commencing ART. Clin. Immunol. 139, 32-39 (2011).
12. Simonney N, Dewulf G, Hermann JL et al. Anti-PGL-Tb1 responses as an indicator of the immune restoration syndrome in HIV-TB patients. Tuberculosis 88(5), 453-461 (2008).
13. Chatterjee D, Hunter SW, McNeil M, Brennan PJ. Lipoarabinomannan. Multiglycosylated form of the mycobacterial mannosylphosphotidylinositols. J. Biol. Chem. 267, 6228-6233 (1992).
14. Hunter SW, Gaylord H, Brennan PJ. Structure and antigenicity of the phosphorylated lipopolysaccharide antigens from the leprosy and tubercle bacilli. J. Biol. Chem. 261, 12345-12351 (1986). (Pubitemid 17202806)
15. Chan J, Fan X, Hunter SW, Brennan PJ, Bloom BR. Lipoarabinomannan, a possible virulence factor involved in persistence of Mycobacterium tuberculosis within macrophages. Infect. Immun. 59(5), 1755-1761 (1991).
16. Da Fonseca DPA J, Joosten D, van der Zee R et al. Identification of new cytotoxic T-Cell epitopes on the 38 kilodalton lipoglycoprotein of Mycobacterium tuberculosis by using lipopeptides. Infect. Immun. 66(7), 3190-3197 (1998). (Pubitemid 28303116)
17. Abebe F, Holm-Hanset C, Wiker HG, Bjune G. Progress in serodiagnosis of Mycobacterium tuberculosis infection. Scand. J. Immunol. 66, 176-191 (2007). (Pubitemid 47063204)
18. Boggian K, Fierz W, Vernazza PL. Infrequent detection of lipoarabinomannan in human immunodeficiency virus-associated mycobacterial disease. Swiss HIV cohort study. J. Clin. Microbiol. 34(7), 1854-1855 (1996). (Pubitemid 26190439)
19. Perkins MD, Cunningham J. Facing the crisis. Improving the diagnosis of tuberculosis in the HIV era. J. Infect. Dis. 196(1), 15-27 (2007).
20. French MA, Price P, Stone SF. Immune restoration disease after antiretroviral therapy. AIDS 18(12), 1615-1627 (2004). (Pubitemid 39095778)
21. Beyene D, Franken Kl, Yamuah L et al. Serodiagnosis of tuberculous lymphadenitis using a combination of antigens. J. Infect. Dev. Ctries 4(2), 96-102 (2010).
22. Mahon RN, Rojas RE, Fulton SA, Franko JL, Harding CV, Boom WH. Mycobacterium tuberculosis cell wall glycolipids directly inhibit CD4+ T-cell activation by interfering with proximal T-cell-receptor signaling. Infect. Immun. 77(10), 4574-4583 (2009).
23. Sousa AO, Henry S, Maroja FM et al. IgG subclass distribution of antibody responses to protein and polysaccharide mycobacterial antigens in leprosy and tuberculosis patients. Clin. Exp. Immunol. 111(1), 49-55 (1998).
24. Demkow U, Filewska M, Michalowska-Mitczuk D et al. Heterogeneity of antibody response to mycobacterial antigens in different clinical manifestations of pulmonary tuberculosis. J. Physiol. Pharmacol. 58(5), 117-127 (2007). (Pubitemid 351346660)
25. World Health Organization. Management of tuberculosis and HIV coinfection. Clinical protocol for the WHO European region (2008). www.euro.who.int/document/SHA/e90840-chapter-4.pdf